Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Justin M Lebenthal,Michael Sun,Jones T. Nauseef,Muhammad Junaid Niaz,Dunya Imad,Paul J. Christos,Escarleth Fernandez,Sharon Singh,Tessa A Chamberlain,Joseph R. Osborne,John W. Babich,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil H. Bander,Scott T. Tagawa

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

2021

Justin M Lebenthal
Michael Sun
Jones T. Nauseef
Muhammad Junaid Niaz
Dunya Imad
Paul J. Christos
Escarleth Fernandez
Sharon Singh
Tessa A Chamberlain
Joseph R. Osborne
John W. Babich
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa

120Background: Elevated CTC counts are associated with a poor prognosis in men with mCRPC. PSMA targeted radionuclide therapy has been associated with decline in CTC count, but it remains unclear w...

Keywords:

PSMA Antibody
Cancer research
Prostate cancer
Glutamate carboxypeptidase II
castration resistant
Circulating tumor cell
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations